Cited by 273Parkinson's Disease Mechanisms and TreatmentsNeurological diseases and metabolismIron Metabolism and Disorders

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Individual dopaminergic neurons show raised iron levels in Parkinson disease

Open access

Oakley, A. E., Collingwood, J. F., Dobson, J., Love, G., Perrott, H. R., Edwardson, J. A., Elstner, M., Morris, C. M.·2007·Neurology

DOI 10.1212/01.wnl.0000262033.01945.9a

Open this paper in CoChat — free account

Abstract

OBJECTIVE: Evidence suggests that abnormal iron metabolism is associated with Parkinson disease (PD), with raised iron levels found in pathologically affected areas in PD. It is unknown if this elevated iron is actually associated with neurons or reactive glia, and we therefore addressed this issue by determining if raised iron was present in single dopaminergic neurons. METHODS: We used unfixed frozen sections from postmortem tissue of PD patients and elderly normal individuals to avoid metal contamination and translocation. Levels of iron and other elements were measured using sensitive and specific wavelength dispersive electron probe x-ray microanalysis coupled with cathodoluminescence spectroscopy in individual substantia nigra dopaminergic neurons. RESULTS: We identified raised intraneuronal iron in single defined substantia nigra neurons in PD (mean neuronal iron 2,838 vs 1,611, p < 0.0001) but not in other movement disorders such as Huntington disease. These findings were unrelated to the density of remaining neurons. CONCLUSIONS: Primary changes in neuronal iron could lead to neurodegeneration in Parkinson disease.

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000262033.01945.9a

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Mitochondrial DNA mutations in human disease
Taylor, R. W., & Turnbull, D. M. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1606 · Cited by 1,922
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G. W. J., Leube, B., Ulm, G., Mezey, É., Harta, G., Brownstein, M., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,599
High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease
Bender, A., Krishnan, K. J., Morris, C. M., Taylor, G. A., Reeve, A. K., Perry, R. H., Jaros, E., Hersheson, J. S., Betts, J., Klopstock, T., et al. (2006) · Nature Genetics · doi:10.1038/ng1769 · Cited by 1,570
Self-citation
The effect of age on the non-haemin iron in the human brain
Hallgren, B., & Sourander, P. (1958) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1958.tb12607.x · Cited by 1,427
Metal-triggered Structural Transformations, Aggregation, and Fibrillation of Human α-Synuclein
Uversky, V. N., Li, J., & Fink, A. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m105343200 · Cited by 1,103
A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome
Zhou, B., Westaway, S. K., Levinson, B., Johnson, M., Gitschier, J. M., & Hayflick, S. J. (2001) · Nature Genetics · doi:10.1038/ng572 · Cited by 756
Genetic, Clinical, and Radiographic Delineation of Hallervorden–Spatz Syndrome
Hayflick, S. J., Westaway, S. K., Levinson, B., Zhou, B., Johnson, M., Ching, K. H. L., & Gitschier, J. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020817 · Cited by 713

Show all 37 references

Research works printed but not linked: 1

Mikhailova A, Davidson M, Channel JET, Guyodo Y, Batich C, Dobson J. Detection, identification and mapping of iron anomalies in brain tissue using x-ray absorption spectroscopy. J Roy Soc Interface 2005;2:33–37.

Sorted by citations

The role of oxidative stress in neurodegenerative diseases
Kim, G. H., Kim, J. E., Rhie, S. J., & Yoon, S. (2015) · Experimental Neurobiology · doi:10.5607/en.2015.24.4.325 · Cited by 1,355
Oxidative Stress in Human Pathology and Aging: Molecular Mechanisms and Perspectives
Hajam, Y. A., Rani, R., Ganie, S. Y., Sheikh, T. A., Javaid, D., Qadri, S. S., Pramodh, S., Alsulimani, A., Alkhanani, M. F., Harakeh, S., et al. (2022) · Cells · doi:10.3390/cells11030552 · Cited by 915
Quantitative susceptibility mapping (QSM): Decoding MRI data for a tissue magnetic biomarker
Wang, Y., & Liu, T. (2015) · Magnetic Resonance in Medicine · doi:10.1002/mrm.25358 · Cited by 878
Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export
Lei, P., Ayton, S., Finkelstein, D. I., Spoerri, L., Ciccotosto, G. D., Wright, D. K., Wong, B. X. W., Adlard, P. A., Cherny, R. A., Lam, L. Q., et al. (2012) · Nature Medicine · doi:10.1038/nm.2613 · Cited by 594
Alzheimer's disease as homeostatic responses to age-related myelin breakdown
Bartzokis, G. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.007 · Cited by 546
Intracellular iron transport and storage: from molecular mechanisms to health implications
Mackenzie, E. L., Iwasaki, K., & Tsuji, Y. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1893 · Cited by 526
Biological metals and metal-targeting compounds in major neurodegenerative diseases
Barnham, K. J., & Bush, A. I. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00138a · Cited by 497
Mitochondrial dysfunction and oxidative stress in Parkinson's disease and monogenic parkinsonism
Hauser, D. N., & Hastings, T. G. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.10.011 · Cited by 487
The Role of Environmental Exposures in Neurodegeneration and Neurodegenerative Diseases
Cannon, J. R., & Greenamyre, J. T. (2011) · Toxicological Sciences · doi:10.1093/toxsci/kfr239 · Cited by 475
Brain iron chelation by deferiprone in a phase 2 randomised double-blinded placebo controlled clinical trial in Parkinson’s disease
Martín‐Bastida, A., Ward, R. J., Newbould, R. D., Piccini, P. P., Sharp, D. J., Kabba, C., Patel, M. C., Spino, M., Connelly, J., Tricta, F., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01402-2 · Cited by 393
Microglia ferroptosis is regulated by SEC24B and contributes to neurodegeneration
Ryan, S. K., Zelic, M., Han, Y., Teeple, E. A., Chen, L., Sadeghi, M., Shankara, S., Guo, L., Li, C., Pontarelli, F., et al. (2022) · Nature Neuroscience · doi:10.1038/s41593-022-01221-3 · Cited by 377
Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
Emerging therapies in Parkinson disease — repurposed drugs and new approaches
Elkouzi, A., Vedam‐Mai, V., Eisinger, R. S., & Okun, M. S. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-019-0155-7 · Cited by 316
Ceruloplasmin dysfunction and therapeutic potential for Parkinson disease
Ayton, S., Lei, P., Duce, J. A., Wong, B. X. W., Sedjahtera, A., Adlard, P. A., Bush, A. I., & Finkelstein, D. I. (2013) · Annals of Neurology · doi:10.1002/ana.23817 · Cited by 264
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases
Chen, L., Shen, Q., Liu, Y., Zhang, Y., Sun, L., Ma, X., Song, N., & Xie, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02071-0 · Cited by 279
The neurotoxicity of iron, copper and manganese in Parkinson's and Wilson's diseases
Dušek, P., Roos, P. M., Litwin, T., Schneider, S. A., Flaten, T. P., & Aaseth, J. (2014) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2014.05.007 · Cited by 260
Brain iron metabolism and its perturbation in neurological diseases
Crichton, R. R., Dexter, D. T., & Ward, R. J. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0470-z · Cited by 247
The transition metals copper and iron in neurodegenerative diseases
Rivera-Mancía, S., Pérez‐Neri, I., Ríos, C., Tristán-López, L. A., Rivera-Espinosa, L., & Montes, S. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.04.010 · Cited by 247
Single Particle Characterization of Iron-induced Pore-forming α-Synuclein Oligomers
Kostka, M., Högen, T., Danzer, K. M., Levin, J., Habeck, M., Wirth, A., Wagner, R., Glabe, C. G., Finger, S., Heinzelmann, U., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709634200 · Cited by 233
Iron regulatory protein (IRP)-iron responsive element (IRE) signaling pathway in human neurodegenerative diseases
Zhou, Z., & Tan, E. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0218-4 · Cited by 241
High resolution magnetic susceptibility mapping of the substantia nigra in Parkinson's disease
Lotfipour, A. K., Wharton, S., Schwarz, S. T., Gontu, V. K., Schäfer, A., Peters, A. M., Bowtell, R. W., Auer, D. P., Gowland, P. A., & Bajaj, N. P. S. (2011) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.22752 · Cited by 210
Brain Iron Homeostasis: From Molecular Mechanisms To Clinical Significance and Therapeutic Opportunities
Singh, N., Haldar, S., Tripathi, A. K., Horback, K., Wong, J., Sharma, D., Beserra, A., Suda, S., Anbalagan, C., Dev, S., et al. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.4931 · Cited by 208
The whole-brain pattern of magnetic susceptibility perturbations in Parkinson’s disease
Acosta‐Cabronero, J., Cárdenas‐Blanco, A., Betts, M. J., Butryn, M., Valdés-Herrera, J. P., Galazky, I., & Nestor, P. J. (2016) · Brain · doi:10.1093/brain/aww278 · Cited by 199
Crosstalk Between Calcium and Redox Signaling: From Molecular Mechanisms to Health Implications
Hidalgo, C., & Donoso, P. (2008) · Antioxidants and Redox Signaling · doi:10.1089/ars.2007.1886 · Cited by 199
A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease
Mastroberardino, P. G., Hoffman, E. K., Horowitz, M. P., Betarbet, R., Taylor, G., Cheng, D., Na, H. M., Gutekunst, C.-A., Gearing, M., Trojanowski, J. Q., et al. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.02.009 · Cited by 195
Mitochondrial iron metabolism and its role in neurodegeneration
Horowitz, M. P., & Greenamyre, J. T. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100354 · Cited by 195
Neuropathology of sporadic Parkinson disease before the appearance of parkinsonism: preclinical Parkinson disease
Ferrer, I., Martinez, A., Blanco, R. E., Dalfó, E., & Carmona, M. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0482-8 · Cited by 191
Targeting dysregulation of brain iron homeostasis in Parkinson's disease by iron chelators
Weinreb, O., Mandel, S. A., Youdim, M. B. H., & Amit, T. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.017 · Cited by 199
Brain Iron Metabolism Dysfunction in Parkinson’s Disease
Jiang, H. F., Wang, J., Rogers, J. T., & Xie, J. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9879-1 · Cited by 188
Mitochondrial Dysfunction in Parkinson's Disease
Keane, P. C., Kurzawa‐Akanbi, M., Blain, P. G., & Morris, C. M. (2011) · Parkinson s Disease · doi:10.4061/2011/716871 · Cited by 182
Self-citation
Analysis of Gene Expression in Parkinson's Disease: Possible Involvement of Neurotrophic Support and Axon Guidance in Dopaminergic Cell Death
Bossers, K., Meerhoff, G. F., Balesar, R. A., van Dongen, J. W., Kruse, C. G., Swaab, D. F., & Verhaagen, J. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00171.x · Cited by 173
Quantitative susceptibility mapping of the midbrain in Parkinson's disease
Du, G., Liu, T., Lewis, M. M., Kong, L., Wang, Y., Connor, J. R., Mailman, R. B., & Huang, X. (2015) · Movement Disorders · doi:10.1002/mds.26417 · Cited by 167
Biology of ferritin in mammals: an update on iron storage, oxidative damage and neurodegeneration
Finazzi, D., & Arosio, P. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1329-0 · Cited by 166
Nigral Iron Elevation Is an Invariable Feature of Parkinson’s Disease and Is a Sufficient Cause of Neurodegeneration
Ayton, S., & Lei, P. (2014) · BioMed Research International · doi:10.1155/2014/581256 · Cited by 163
Cerebral Iron Deposition in Neurodegeneration
Dušek, P., Hofer, T., Alexander, J., Roos, P. M., & Aaseth, J. (2022) · Biomolecules · doi:10.3390/biom12050714 · Cited by 170
Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: An in vivo MR study
Zhang, J., Zhang, Y., Wang, J., Cai, P., Luo, C., Qian, Z., Dai, Y., & Feng, H. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.036 · Cited by 158
The Effects of Polyphenols on Survival and Locomotor Activity in Drosophila melanogaster Exposed to Iron and Paraquat
Jiménez-Del-Río, M., Guzman‐Martínez, C., & Velez‐Pardo, C. (2009) · Neurochemical Research · doi:10.1007/s11064-009-0046-1 · Cited by 153
Pro-inflammatory cytokines modulate iron regulatory protein 1 expression and iron transportation through reactive oxygen/nitrogen species production in ventral mesencephalic neurons
Wang, J., Song, N., Jiang, H., Wang, J., & Xie, J. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.021 · Cited by 150
Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease
Rogers, J. T., Bush, A. I., Cho, H.-H., Smith, D. H., Thomson, A. M., Friedlich, A. L., Lahiri, D. K., Leedman, P. J., Huang, X., & Cahill, C. M. (2008) · Biochemical Society Transactions · doi:10.1042/bst0361282 · Cited by 148
Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer’s Disease, Parkinson’s Disease, and Intracerebral Hemorrhage
Farr, A. C., & Xiong, M. P. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00474 · Cited by 154
Evidence for Gender-Specific Transcriptional Profiles of Nigral Dopamine Neurons in Parkinson Disease
Šimunović, F., Yi, M., Wang, Y., Stephens, R. M., & Sonntag, K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008856 · Cited by 141
Association between Heavy Metal Exposure and Parkinson’s Disease: A Review of the Mechanisms Related to Oxidative Stress
Pyatha, S., Kim, H., Lee, D., & Kim, K. (2022) · Antioxidants · doi:10.3390/antiox11122467 · Cited by 140
Physical training exerts neuroprotective effects in the regulation of neurochemical factors in an animal model of Parkinson’s disease
Tuon, T., Valvassori, S. S., Lopes-Borges, J., Luciano, T. F., Tromm, C. B., da Silva, L. A., Quevedo, J., de Souza, C. T., Lira, F. S., & Pinho, R. A. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.09.063 · Cited by 139
Impact of aging, Alzheimer's disease and Parkinson's disease on the blood-brain barrier transport of therapeutics
Pan, Y., & Nicolazzo, J. A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.04.009 · Cited by 131
Iron, the substantia nigra and related neurological disorders
Snyder, A. M., & Connor, J. R. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.08.005 · Cited by 138
Disrupted iron homeostasis causes dopaminergic neurodegeneration in mice
Matak, P., Matak, A., Moustafa, S. M., Aryal, D. K., Benner, E. J., Wetsel, W. C., & Andrews, N. C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1519473113 · Cited by 136
Parkinson's Disease Iron Deposition Caused by Nitric Oxide-Induced Loss of β-Amyloid Precursor Protein
Ayton, S., Lei, P., Hare, D. J., Duce, J. A., George, J. L., Adlard, P. A., McLean, C., Rogers, J. T., Cherny, R. A., Finkelstein, D. I., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.3439-14.2015 · Cited by 131
Ceruloplasmin oxidation, a feature of Parkinson's disease CSF, inhibits ferroxidase activity and promotes cellular iron retention
Olivieri, S., Conti, A., Iannaccone, S., Cannistraci, C. V., Campanella, A., Barbariga, M., Codazzi, F., Pelizzoni, I., Magnani, G., Pesca, M., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.3768-11.2011 · Cited by 125
Cathodoluminescence for the 21st century: Learning more from light
Coenen, T., & Haegel, N. M. (2017) · Applied Physics Reviews · doi:10.1063/1.4985767 · Cited by 124
Selective cell death in neurodegeneration: Why are some neurons spared in vulnerable regions?
Double, K. L., Reyes, S., Werry, E. L., & Halliday, G. M. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.001 · Cited by 126
Universality of protein reentrant condensation in solution induced by multivalent metal ions
Zhang, F., Weggler, S., Ziller, M. J., Ianeselli, L., Heck, B. S., Hildebrandt, A., Kohlbacher, O., Skoda, M. W. A., Jacobs, R. M. J., & Schreiber, F. (2010) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.22852 · Cited by 123
Metal imaging in neurodegenerative diseases
Bourassa, M. W., & Miller, L. M. (2012) · Metallomics · doi:10.1039/c2mt20052j · Cited by 125
Up-regulation of divalent metal transporter 1 in 6-hydroxydopamine intoxication is IRE/IRP dependent
Jiang, H. F., Song, N., Xu, H., Zhang, S., Wang, J., & Xie, J. (2010) · Cell Research · doi:10.1038/cr.2010.20 · Cited by 121
Lipopolysaccharide animal models of Parkinson’s disease: Recent progress and relevance to clinical disease
Deng, I. B., Corrigan, F., Zhai, G., Zhou, X., & Bobrovskaya, L. (2020) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2020.100060 · Cited by 129
Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1α and induction of autophagy in SH-SY5Y cells
Wu, Y., Li, X., Xie, W., Jankovic, J. J., Le, W., & Pan, T. (2010) · Neurochemistry International · doi:10.1016/j.neuint.2010.05.008 · Cited by 115
Iron in Multiple Sclerosis and Its Noninvasive Imaging with Quantitative Susceptibility Mapping
Stüber, C., Pitt, D., & Wang, Y. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17010100 · Cited by 117
Novel targeted therapies for Parkinson’s disease
Ntetsika, T., Papathoma, P.-E., & Markaki, I. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00279-2 · Cited by 120
Recent Advances in Drug Therapy for Parkinson's Disease
Murakami, H., Shiraishi, T., Umehara, T., Omoto, S., & Iguchi, Y. (2022) · Internal Medicine · doi:10.2169/internalmedicine.8940-21 · Cited by 114
Ferroportin 1 but not hephaestin contributes to iron accumulation in a cell model of Parkinson's disease
Song, N., Wang, J., Jiang, H. F., & Xie, J. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.11.004 · Cited by 111
Mitochondrial iron-sulfur cluster dysfunction in neurodegenerative disease
Isaya, G. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00029 · Cited by 109
Common and Trace Metals in Alzheimer’s and Parkinson’s Diseases
Doroszkiewicz, J., Farhan, J. A., Mroczko, J., Winkel, I., Perkowski, M., & Mroczko, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115721 · Cited by 108
Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases
Cahill, C. M., Lahiri, D. K., Huang, X., & Rogers, J. T. (2008) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2008.12.001 · Cited by 108
Assessing Plasma Levels of Selenium, Copper, Iron and Zinc in Patients of Parkinson’s Disease
Hai-wen, Z., Lin, J., Wang, X., Cheng, X., Wang, J., Hu, B., Zhang, Y., Zhang, X., & Zhu, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083060 · Cited by 109
The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson’s disease
Finkelstein, D. I., Billings, J. L., Adlard, P. A., Ayton, S., Sedjahtera, A., Masters, C. L., Wilkins, S., Shackleford, D. M., Charman, S. A., Bal, W., et al. (2017) · Acta Neuropathologica Communications · doi:10.1186/s40478-017-0456-2 · Cited by 104
Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells
Perfeito, R., Lázaro, D. F., Outeiro, T. F., & Rego, A. C. (2014) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2014.08.002 · Cited by 105
Interactions between iron and α-synuclein pathology in Parkinson's disease
Chen, B., Wen, X., Jiang, H. F., Wang, J., Song, N., & Xie, J. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.06.024 · Cited by 107
Acute and chronic metal exposure impairs locomotion activity in Drosophila melanogaster: a model to study Parkinsonism
Bonilla-Ramírez, L., Jiménez-Del-Río, M., & Velez‐Pardo, C. (2011) · BioMetals · doi:10.1007/s10534-011-9463-0 · Cited by 98
The Relevance of Metals in the Pathophysiology of Neurodegeneration, Pathological Considerations
Jellinger, K. A. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-410502-7.00002-8 · Cited by 101
Iron–sulfur cluster biosynthesis and trafficking – impact on human disease conditions
Wachnowsky, C., Fidai, I., & Cowan, J. A. (2017) · Metallomics · doi:10.1039/c7mt00180k · Cited by 99
LRRK2 inhibition prevents endolysosomal deficits seen in human Parkinson's disease
Rocha, E. M., Miranda, B. R. D., Castro, S. L., Drolet, R. E., Hatcher, N. G., Yao, L., Smith, S. M., Keeney, M. T., Maio, R. D., Kofler, J., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104626 · Cited by 97
Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders
Wise, R. M., Wagener, A., Fietzek, U. M., Klopstock, T., Mosharov, E. V., Zucca, F. A., Sulzer, D., Zecca, L., & Burbulla, L. F. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105920 · Cited by 96
Role of iron in neurotoxicity: a cause for concern in the elderly?
Stankiewicz, J., & Brass, S. D. (2008) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0b013e32831ba07c · Cited by 94
Dietary Iron Intake and Risk of Parkinson's Disease
Logroscino, G., Gao, X., Chen, H., Wing, A., & Ascherio, A. (2008) · American Journal of Epidemiology · doi:10.1093/aje/kwn273 · Cited by 93
Molecular changes in the postmortem parkinsonian brain
Toulorge, D., Schapira, A. H. V., & Hajj, R. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13696 · Cited by 95
Cannabidiol normalizes caspase 3, synaptophysin, and mitochondrial fission protein DNM1L expression levels in rats with brain iron overload: implications for neuroprotection
da Silva, V. K., de Freitas, B. S., da Silva Dornelles, A., Nery, L. R., Falavigna, L., Ferreira, R. D. P., Bogo, M. R., Hallak, J. E. C., Zuardi, A. W., Crippa, J. A. S., et al. (2014) · Molecular Neurobiology · doi:10.1007/s12035-013-8514-7 · Cited by 91
A Review on Lactoferrin and Central Nervous System Diseases
Li, Y.-Q., & Guo, C. (2021) · Cells · doi:10.3390/cells10071810 · Cited by 92
Can the emerging field of immunometabolism provide insights into neuroinflammation?
Lynch, M. A. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101719 · Cited by 88
Pathogenesis of α-Synuclein in Parkinson’s Disease: From a Neuron-Glia Crosstalk Perspective
Yi, S., Wang, L., Wang, H., Ho, M. S.-C., & Zhang, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314753 · Cited by 96
Lateral Asymmetry and Spatial Difference of Iron Deposition in the Substantia Nigra of Patients with Parkinson Disease Measured with Quantitative Susceptibility Mapping
Azuma, M., Hirai, T., Yamada, K., Yamashita, S., Ando, Y., Tateishi, M., Iryo, Y., Yoneda, T., Kitajima, M., Wang, Y., et al. (2016) · American Journal of Neuroradiology · doi:10.3174/ajnr.a4645 · Cited by 88
Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin
Rhodes, S. L., Buchanan, D. D., Ahmed, I., Taylor, K. D., Loriot, M., Sinsheimer, J. S., Bronstein, J. M., Elbaz, A., Mellick, G. D., Rotter, J. I., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.09.019 · Cited by 87
Deferoxamine-mediated up-regulation of HIF-1α prevents dopaminergic neuronal death via the activation of MAPK family proteins in MPTP-treated mice
Guo, C., Hao, L.-J., Yang, Z., Chai, R., Zhang, S., Gu, Y., Gao, H., Zhong, M., Wang, T., Li, J., et al. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.03.016 · Cited by 87
Nuclear factor‐kappa B (NF‐κB) in pathophysiology of Parkinson disease: Diverse patterns and mechanisms contributing to neurodegeneration
Dolatshahi, M., Hameghavandi, M. H. R., Sabahi, M., & Rostamkhani, S. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.15242 · Cited by 87
Associations between moderate alcohol consumption, brain iron, and cognition in UK Biobank participants: Observational and mendelian randomization analyses
Topiwala, A., Wang, C., Ebmeier, K. P., Burgess, S., Bell, S., Levey, D. F., Zhou, H., McCracken, C., Roca‐Fernández, A., Petersen, S. E., et al. (2022) · PLoS Medicine · doi:10.1371/journal.pmed.1004039 · Cited by 79
Quantitative micro-analysis of metal ions in subcellular compartments of cultured dopaminergic cells by combination of three ion beam techniques
Carmona, A., Devès, G., & Ortega, R. (2008) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-008-1866-6 · Cited by 88
The alpha-synuclein 5′untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen
Rogers, J. T., Mikkilineni, S., Cantuti‐Castelvetri, I., Smith, D. H., Huang, X., Bandyopadhyay, S., Cahill, C. M., Maccecchini, M. L., Lahiri, D. K., & Greig, N. H. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-010-0513-5 · Cited by 82
Ferroptosis and Iron Homeostasis: Molecular Mechanisms and Neurodegenerative Disease Implications
Abdukarimov, N., Kokabi, K., & Kunz, J. (2025) · Antioxidants · doi:10.3390/antiox14050527 · Cited by 93
Oxidized DJ-1 as a possible biomarker of Parkinson’s disease
Saito, Y. (2014) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.13-108 · Cited by 83
Iron-dependent functions of mitochondria—relation to neurodegeneration
Gille, G., & Reichmann, H. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0503-7 · Cited by 77
Intranasal administration of α-synuclein preformed fibrils triggers microglial iron deposition in the substantia nigra of Macaca fascicularis
Guo, J., Yue, F., Song, D., Bousset, L., Liang, X., Tang, J., Yuan, L., Li, W., Melki, R., Tang, Y. C., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-020-03369-x · Cited by 74
Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: Maintenance of brain iron homeostasis
Bandyopadhyay, S., & Rogers, J. T. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.032 · Cited by 77
Nano-imaging of trace metals by synchrotron X-ray fluorescence into dopaminergic single cells and neurite-like processes
Carmona, A., Cloetens, P., Devès, G., Bohic, S., & Ortega, R. (2008) · Journal of Analytical Atomic Spectrometry · doi:10.1039/b802242a · Cited by 77
Oxidative Stress Partially Contributes to Iron-Induced Alpha-Synuclein Aggregation in SK-N-SH Cells
Li, W., Jiang, H. F., Song, N., & Xie, J. (2010) · Neurotoxicity Research · doi:10.1007/s12640-010-9187-x · Cited by 73
Sequential Multiple-Target Sensor: In3+, Fe2+, and Fe3+ Discrimination by an Anthracene-Based Probe
Finelli, A., Chabert, V., Hérault, N., Crochet, A., Kim, C., & Fromm, K. M. (2019) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.9b01478 · Cited by 71
Hinokitiol functions as a ferroptosis inhibitor to confer neuroprotection
Xi, J., Zhang, Z., Wang, Z., Wu, Q., He, Y., Xu, Y., Ding, Z., Zhao, H., Da, H., Zhang, F., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.08.011 · Cited by 69
Caenorhabditis elegans: a model to investigate oxidative stress and metal dyshomeostasis in Parkinson's disease
Chege, P. M., & McColl, G. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00089 · Cited by 68
Cell specific quantitative iron mapping on brain slices by immuno-µPIXE in healthy elderly and Parkinson’s disease
Friedrich, I., Reimann, K., Jankuhn, S., Kirilina, E. P., Stieler, J., Sonntag, M., Meijer, J., Weiskopf, N., Reinert, T., Arendt, T., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01145-2 · Cited by 70
Elemental mapping of Neuromelanin organelles of human Substantia Nigra: correlative ultrastructural and chemical analysis by analytical transmission electron microscopy and nano‐secondary ion mass spectrometry
Biesemeier, A., Eibl, O., Eswara, S., Audinot, J., Wirtz, T., Pezzoli, G., Zucca, F. A., Zecca, L., & Schraermeyer, U. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13648 · Cited by 68
Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model
Febbraro, F., Andersen, K. J., Sánchez-Guajardo, V., Tentillier, N., & Romero‐Ramos, M. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.03.017 · Cited by 66
Substantia nigra echogenicity: A structural correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease
Weise, D., Lorenz, R., Schließer, M., Schirbel, A., Reiners, K., & Claßen, J. (2009) · Movement Disorders · doi:10.1002/mds.22665 · Cited by 64
α-Synuclein impairs ferritinophagy in the retinal pigment epithelium: Implications for retinal iron dyshomeostasis in Parkinson’s disease
Baksi, S., & Singh, N. (2017) · Scientific Reports · doi:10.1038/s41598-017-12862-x · Cited by 64

Authors: Oakley, A. E., Collingwood, J. F., Dobson, J., Love, G., Perrott, H. R., Edwardson, J. A., Elstner, M., & Morris, C. M.
Affiliations: University of Bath (GB)
ORCID: Collingwood, J. F.
Dobson, J.
Morris, C. M.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2007-05-22
Volume: 68
Issue: 21
Pages: 1820-1825
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/01.wnl.0000262033.01945.9a
OpenAlex: W2100919899
Cited by: 273
References: 37
Citations by year: 2026: 8 · 2025: 10 · 2024: 12 · 2023: 9 · 2022: 18 · 2021: 16 · 2020: 20 · 2019: 14 · 2018: 11 · 2017: 19 · 2016: 15 · 2015: 11 · 2014: 17 · 2013: 15 · 2012: 12
FWCI: 11.23
Type: journal article
Language: en
Open access: green
doi.org
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
Newcastle University ePrints (Newcastle Univesity)
Funders: Engineering and Physical Sciences Research Council (EP/D066654/1)
National Institute on Aging (R01 AG 02030-01)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Neuroscience › Neurology › Neurological diseases and metabolism
Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
Keywords: Parkinson's disease, dopaminergic neurons, substantia nigra, iron metabolism, neurodegeneration, Huntington's disease, reactive glia
MeSH terms: Adult, Aged, Aged, 80 and over, Brain Chemistry, Cell Count, Dopamine, Electron Probe Microanalysis, Ferritins, Humans, Iron, Middle Aged, Neuroglia, Neurons, Parkinson Disease, Predictive Value of Tests, Spectrum Analysis, Substantia Nigra, Biomarkers, Up-Regulation, Iron Metabolism Disorders, Neuropil

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Individual dopaminergic neurons show raised iron levels in Parkinson disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks